webinar register page

Webinar banner
SGLT2 inhibitors: Can these drugs slow the progression of chronic kidney disease?
Our guest speakers will cover what all kidney patients need to know on a new class of drugs: SGLT inhibitors, canagliflozin and dapagliflozin. Dr. Vivian Jan Tarkul will highlight the CREDENCE Trial and DAPA-CKD Trial. Joining her will be Nephrologist Patrick Cunningham Ahearn, MD, MAS, Stanford Health Care and clinical assistant professor at the Stanford University School of Medicine Division of Nephrology who will answer questions of concern for chronic kidney patients.

Oct 23, 2022 01:00 PM in Pacific Time (US and Canada)

Webinar logo
* Required information